Dan-Yun Lai

Dan-Yun Lai

Auto-generated profile, based on publicly available information

Dan-Yun Lai

Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200240, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2022 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
HQHuan Qi
Huan Qi
JXJun‐Biao Xue
Jun‐Biao Xue
DLDan‐Yun Lai
Dan‐Yun Lai
ALAng Li
Ang Li
Shengce TaoShengce Tao
Shengce Tao

5 November 2021 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
ZXZhaowei Xu
Zhaowei Xu
YLYang Li
Yang Li
QLQing Lei
Qing Lei
LHLikun Huang
Likun Huang
DLDan-Yun Lai
Dan-Yun Lai
Shengce TaoShengce Tao
Shengce Tao
Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, varies with regard to symptoms and mortality rates among populations. Humoral immunity plays critical roles in SARS-CoV-2 infection and recovery from COVID-19. However, differences in immune responses and clinical features among COVID-19 patients remain largely unknown. Here, we report a database for COVID-19-specific IgG/IgM immune responses and clinical parameters (named COVID-ONE-hi). COVID-ONE-hi is based on the data that contain the IgG/IgM responses to 24 full-length/truncated proteins corresponding to 20 of 28 known SARS-CoV-2 proteins and 199 spike protein peptides against 2360 serum samples collected from 783 COVID-19 patients. In addition, 96 clinical parameters for the 2360 serum samples and basic information for the 783 patients are integrated into the database. Furthermore, COVID-ONE-hi provides a dashboard for defining samples and a one-click analysis pipeline for a single group or paired groups. A set of samples of interest is easily defined by adjusting the scale bars of a variety of parameters. After the “START” button is clicked, one can readily obtain a comprehensive analysis report for further interpretation. COVID-ONE-hi is freely available at www.COVID-ONE.cn.

28 February 2022 in STAR Protocols
Verified
Journal Article
Open access
DLDan-Yun Lai
Dan-Yun Lai
HJHe-Wei Jiang
He-Wei Jiang
YLYang Li
Yang Li
HZHai-Nan Zhang
Hai-Nan Zhang
Shengce TaoShengce Tao
Shengce Tao
The immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteome is largely unknown. Here we describe a protocol for analyzing sera samples with SARS-CoV-2 proteome microarray. The proteins were ex-pressed by either E. coli expression system or eukaryotic cell expression systems and obtained by affinity purification. The protocol includes microarray fabri-cating and sera profiling, which will be used to build an antibody response land-scape for IgG and IgM. The protocol may help to facilitate a deeper understand-ing of immunity related to SARS-CoV-2.For complete details on the use and execution of this protocol, please refer to Li et al. (2021c).

1 January 2020 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
YLYang Li
Yang Li
MMMing-Liang Ma
Ming-Liang Ma
QLQing Lei
Qing Lei
FWFeng Wang
Feng Wang
DLDan-Yun Lai
Dan-Yun Lai
Shengce TaoShengce Tao
Shengce Tao
Neutralization antibodies and vaccines for treating COVID-19 are desperately needed. For precise development of antibodies and vaccines, the key is to understand which part of SARS-CoV-2 Spike protein is highly immunogenic on a systematic way. We generate a linear epitope landscape of Spike protein by analyzing serum IgG response of 1,051 COVID-19 patients with a peptide microarray. We reveal two regions that rich of linear epitopes, i.e., CTD and a region close to the S2’ cleavage site and fusion peptide. Unexpectedly, we find RBD is lack of linear epitope. Besides 3 moderate immunogenic peptides from RBD, 16 highly immunogenic peptides from other regions of Spike protein are determined. These peptides could serve as the base for precise development of antibodies and vaccines for COVID-19 on a systematic level. Funding: This work was partially supported by National Key Research and Development Program of China Grant (No. 2016YFA0500600), Science and Technology Commission of Shanghai Municipality (No. 19441911900), Interdisciplinary Program of Shanghai Jiao Tong University (No. YG2020YQ10), National Natural Science Foundation of China (No. 31970130, 31600672, 31670831, and 31370813). Conflict of Interest: The authors declare no competing interest.

30 July 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
ZXZhaowei Xu
Zhaowei Xu
YLYang Li
Yang Li
QLQing Lei
Qing Lei
LHLikun Huang
Likun Huang
DLDan-Yun Lai
Dan-Yun Lai
Shengce TaoShengce Tao
Shengce Tao
Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, varies with regard to symptoms and mortality rates among populations. Humoral immunity plays critical roles in SARS-CoV-2 infection and recovery from COVID-19. However, differences in immune responses and clinical features among COVID-19 patients remain largely unknown. Here, we report a database for COVID-19-specific IgG/IgM immune responses and clinical parameters (COVID-ONE humoral immune). COVID-ONE humoral immunity is based on a dataset that contains the IgG/IgM responses to 21 of 28 known SARS-CoV-2 proteins and 197 spike protein peptides against 2,360 COVID-19 samples collected from 783 patients. In addition, 96 clinical parameters for the 2,360 samples and information for the 783 patients are integrated into the database. Furthermore, COVID-ONE humoral immune provides a dashboard for defining samples and a one-click analysis pipeline for a single group or paired groups. A set of samples of interest is easily defined by adjusting the scale bars of a variety of parameters. After the “START” button is clicked, one can readily obtain a comprehensive analysis report for further interpretation. COVID-ONE-humoral immune is freely available at www.COVID-ONE.cn .

1 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ZXZhaowei Xu
Zhaowei Xu
YLYang Li
Yang Li
QLQing Lei
Qing Lei
LHLikun Huang
Likun Huang
DLDan-Yun Lai
Dan-Yun Lai
Shengce TaoShengce Tao
Shengce Tao
Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, varies with regard to symptoms and mortality rates among populations. Humoral immunity plays critical roles in SARS-CoV-2 infection and recovery from COVID-19. However, differences in immune responses and clinical features among COVID-19 patients remain largely unknown. Here, we report a database for COVID-19-specific IgG/IgM immune responses and clinical parameters (COVID-ONE humoral immune). COVID-ONE humoral immunity is based on a dataset that contains the IgG/IgM responses to 21 of 28 known SARS-CoV-2 proteins and 197 spike protein peptides against 2,360 COVID-19 samples collected from 783 patients. In addition, 96 clinical parameters for the 2,360 samples and information for the 783 patients are integrated into the database. Furthermore, COVID-ONE humoral immune provides a dashboard for defining samples and a one-click analysis pipeline for a single group or paired groups. A set of samples of interest is easily defined by adjusting the scale bars of a variety of parameters. After the “START” button is clicked, one can readily obtain a comprehensive analysis report for further interpretation. COVID-ONE-humoral immune is freely available at www.COVID-ONE.cn .